Lipoatrophy, lipodystrophy, and insulin resistance.
O P
OP
Ganda
D001823:Body Composition / Q000187:drug effects; D002839:Chromans / Q000627:therapeutic use*; D003923:Diabetes Mellitus, Lipoatrophic / Q000188:drug therapy* / Q000503:physiopathology*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007333:Insulin Resistance; D008060:Lipodystrophy / Q000188:drug therapy* / Q000503:physiopathology*; D013577:Syndrome; D013844:Thiazoles / Q000627:therapeutic use*; D045162:Thiazolidinediones; D000077288:Troglitazone
D002839:Chromans; D007004:Hypoglycemic Agents; D013844:Thiazoles; D045162:Thiazolidinediones; D000077288:Troglitazone